Phase 3 Migraine Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with migraine (with or without aura) according to standard medical guidelines, and have had chronic migraine for at least 6 months before the screening visit.
- People who are willing and able to complete a daily headache diary on at least 23 out of the 28 days during the screening period.
- People who, during the 28-day screening period, experience between 15 and 26 headache days in total, with at least 8 of those days being migraine days, as recorded in the diary.
Who may not be able to join:
- People who have previously taken part in this same study and received the study drug, eptinezumab.
- People who have received any monoclonal antibody treatment (including as part of another study) within the 6 months before the screening visit.
- People who have received any CGRP antibody treatment — a specific type of medication used for migraine prevention — (including as part of another study) within the 6 months before the screening visit.
- People who have a history or diagnosis of certain specific headache or migraine types, including complicated migraine, chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or rarer migraine subtypes such as hemiplegic migraine, migraine with brainstem aura, ophthalmoplegic migraine, or migraine with unusual neurological symptoms not typical of standard migraine aura (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Email contact via H. Lundbeck A/S, H. Lundbeck A/S
Phone: +45 36301311
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change From Baseline in Monthly Migraine Days (MMDs) Averaged Over Weeks 1-12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.